Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 21, 2025, discloses the granting of conditional share awards under the GlaxoSmithKline 2017 Performance Share Plan. The awards were granted on February 17, 2025, to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The performance period for these awards spans three financial years, from January 1, 2025, to December 31, 2027.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation transactions. Key transaction details include:
- Instrument Type: Conditional awards of Ordinary Shares (ISIN: GB00BN7SWP63) and American Depositary Shares (ADS) (ISIN: US37733W2044).
- Valuation Price: Ordinary Shares were valued at £14.35 per share (with one exception at £14.195). ADS were valued at $36.17 per share.
- Total Volume: The filing lists individual award volumes for 13 executives, totaling approximately 2,452,197 Ordinary Shares and 69,302 ADS.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It serves as a regulatory notification of new equity-based compensation grants. The specific performance measures applicable to the 2025 awards are not detailed in this document and will be disclosed in a separate release and the 2024 Annual Report.
Guidance, Outlook, and Risks
Vesting Conditions: The percentage of awards that vest is dependent on the achievement of performance targets set by the Remuneration Committee. Unvested elements will lapse at the end of the three-year period.
Holding Period: For Executive Directors, an additional two-year holding period applies after the normal vesting date, resulting in a total five-year retention requirement. Shares are only forfeited during this period if the director is terminated for cause.
Dividends: Dividends accrue on the conditional awards during the performance period but only vest if the underlying awards vest. These accrued dividends are not included in the transaction volumes listed.
Investor Verification Checklist
- Verify the specific performance targets for the 2025-2027 period in the upcoming 2024 Annual Report or separate release.
- Confirm the total number of shares granted to ensure alignment with the company's overall equity compensation budget.
- Review the "Holding Period" restrictions for Executive Directors to understand potential future share liquidity constraints.
- Monitor the separate release for details on the performance measures, as they are not defined in this filing.